(Q30416847)

English

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

phase II clinical trial

0 references

zoledronic acid

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mariana Chavez-MacGregor

6

object named as

Mariana Chavez-MacGregor

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

Kathryn M. Trinkaus

3

object named as

Kathryn Trinkaus

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Rebecca Aft

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Michael Naughton

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Mark Watson

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lourdes Ylagan

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jing Zhai

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sacha Kuo

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

William Shannon

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Kathryn Diemer

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Virginia Herrmann

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jill Dietz

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Amjad Ali

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Matthew Ellis

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peter Weiss

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Timothy Eberlein

16

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Cynthia Ma

17

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Paula M Fracasso

18

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Imran Zoberi

19

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Marie Taylor

20

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

William Gillanders

21

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Timothy Pluard

22

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Joanne Mortimer

23

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Katherine Weilbaecher

24

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

31 March 2010

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

421-428

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Cancer micrometastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Antitumor effects of bisphosphonates: promising preclinical evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Skeletal complications of breast cancer therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Zoledronic acid: past, present and future roles in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Mechanisms of osteolytic bone metastases in breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

20 June 2018

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Zoledronic acid(ZOMETA): a significant improvement in the bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

A pooled analysis of bone marrow micrometastasis in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Release of tumor cells from bone marrow.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3792651

26 November 2018

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20362507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(10)70054-1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30416847&oldid=1966925484"